مقایسه کتابهای اطلاعات دارویی : تجویز دوز

جمعه چهاردهم بهمن 1390

 

بعد از اینکه کتابهای اطلاعات دارویی رو از نظر جامع بودن نگارش عوارض بررسی کردیم نوبت به مقایسه تجویز و کاربرد داروها در بیماریهای مختلف هست.

باز هم داروی پنتوپرازول در تمام این کتابها مقایسه میشن.

به نظر من ترتیب جامع بودن به این صورت هست و اگه بخوایم راحتی رجوع رو در نظر بگیریم گزینه اول فکت میشه.

۱- AHFS Drug Information

۲- A to Z Drug Facts

۳- Nursing 2012 Drug Handbook

۴- British National Formulary 59th edition

۵- Mosby's Nursing Drug Reference

۶- Jones 2012 Nurse's Drug Handbook

۷- DRUG GUIDE for Physicians

۸- Pearson Nurse's Drug Guide

۹- Saunders Nursing Drug Handbook 2010

۱۰- Lippincott's Nursing Drug Guide

۱۱- Clinician's Pocket Drug Reference 2009

 


 

۱- AHFS Drug Information (AHFS-DI™) | Version: 14.9.2/2011.12.20

 

Dosage and Administration

Reconstitution and Administration

Pantoprazole sodium is administered orally or IV; the drug is not intended for other parenteral routes of administration. Pantoprazole is administered once daily in the management of gastroesophageal reflux disease (GERD) and erosive esophagitis; in the management of pathologic GI hypersecretory conditions, pantoprazole generally is given twice daily, although the drug may be given IV every 8 hours if necessary.

For the treatment of GERD, one vial of pantoprazole sodium for injection should be reconstituted with 10 mL of 0.9% sodium chloride injection to provide a solution containing about 4 mg/mL of pantoprazole; the reconstituted solution may be stored for up to 24 hours at room temperature and does not need to be protected from light prior to IV injection over not less than 2 minutes. Alternatively, the reconstituted solution may be stored for up to 6 hours at room temperature prior to further dilution with 100 mL of 0.9% sodium chloride injection, 5% dextrose injection, or lactated Ringer’s injection to provide a final concentration of about 0.4 mg/mL. The diluted solution may be stored at room temperature but must be used within 24 hours after initial reconstitution. Neither the reconstituted nor diluted solution needs to be protected from light. The diluted solution may be infused IV over a period of about 15 minutes (about 2.7 mg of the drug or 7 mL of solution per minute).

For the treatment of hypersecretory conditions, each of two 40-mg (of pantoprazole) vials of pantoprazole sodium for injection should be reconstituted with 10 mL of 0.9% sodium chloride injection; the total volume (approximately 20 mL) of reconstituted solution may be stored for up to 24 hours at room temperature and does not need to be protected from light prior to IV injection over not less than 2 minutes. Alternatively, the contents of both vials may be combined and stored for up to 6 hours at room temperature prior to further dilution with 80 mL of 0.9% sodium chloride injection, 5% dextrose injection, or lactated Ringer’s injection to a final volume of about 100 mL, providing a final concentration of about 0.8 mg/mL. The diluted solution may be stored at room temperature but must be used within 24 hours after initial reconstitution. Neither the reconstituted nor diluted solution needs to be protected from light. The diluted solution may be infused IV over a period of about 15 minutes (about 5.3 mg of the drug or 7 mL of solution per minute).

Health-care personnel (e.g., pharmacists, nurses) preparing reconstituted solutions using spiked IV system adapters should use caution because of the potential for breakage of the glass vial. (See Glass Vial Breakage under Warnings/Precautions: General Precautions, in Cautions.)

Pantoprazole sodium should be administered IV through a dedicated IV line or via a Y-site. Parenteral pantoprazole sodium solutions should be inspected visually for particulate matter and discoloration prior to and during administration whenever solution and container permit. Pantoprazole sodium for injection is incompatible by Y-site administration with midazolam hydrochloride injection and may be incompatible with solutions containing zinc. Y-site administration of IV pantoprazole should be discontinued immediately if precipitation or discoloration occurs.

Pantoprazole sodium delayed-release tablets should be swallowed intact and not split, crushed, or chewed. For patients unable to swallow the 40-mg tablets, a 40-mg dose may be administered using two 20-mg tablets. Food may delay the rate but does not affect the extent of GI absorption of the tablets; therefore, pantoprazole delayed-release tablets may be administered without regard to meals. Antacids do not affect the absorption of pantoprazole and may be administered concomitantly with the delayed-release tablets.

Pantoprazole delayed-release oral suspension should be administered 30 minutes before a meal. Pantoprazole sodium delayed-release granules for oral suspension should be mixed with applesauce or apple juice prior to administration; the granules should not be mixed with any other foods or liquids (including water). The delayed-release granules in the suspension should be swallowed intact and not crushed or chewed. The contents of a single-dose packet of pantoprazole sodium delayed-release granules for oral suspension should be sprinkled onto one teaspoonful of applesauce and administered within 10 minutes of preparation. Alternatively, the contents of a single-dose packet may be sprinkled into 5 mL of apple juice; the resulting suspension should be stirred for 5 seconds and then swallowed immediately. The container should be rinsed once or twice with apple juice and the rinsings swallowed immediately to ensure complete delivery of the dose.

Pantoprazole delayed-release oral suspension also can be administered via a nasogastric tube (16 French or larger). The plunger should be removed from a 60-mL syringe and the catheter tip of the syringe attached to the nasogastric tube; then, the contents of a single-dose packet of pantoprazole sodium delayed-release granules for oral suspension should be emptied into the barrel of the syringe while the syringe is held as high as possible to prevent bending of the tubing. A volume of 10 mL of apple juice should be added to the syringe and the syringe gently tapped or shaken to facilitate emptying; the syringe and tubing should be rinsed with 10 mL of apple juice at least 2 more times (until no granules remain) and the patency of the tubing should be verified to ensure complete delivery of the dose.

For the treatment of pathologic hypersecretory conditions associated with Zollinger-Ellison syndrome or other neoplastic conditions, pantoprazole sodium for injection is administered IV every 8 or 12 hours. The frequency of administration may be individualized based on acid output measurements. Patients with Zollinger-Ellison syndrome may be vulnerable to serious complications of increased gastric acid secretion, even after a brief loss of gastric acid suppression. Therefore, transition from oral to IV and IV to oral formulations of gastric acid inhibitors should be performed in such a manner to ensure continuity of gastric acid suppression effects.

Dosage Sorry No Image

Pending revision, the material in this section should be considered in light of more recently available information in the MedWatch notification at the beginning of this monograph.

Dosage of pantoprazole sodium is expressed in terms of pantoprazole.

For the treatment of erosive esophagitis associated with GERD, the recommended adult oral dosage of pantoprazole is 40 mg daily. The duration of therapy is 8 weeks, and therapy may be extended for an additional 8 weeks if esophageal healing is incomplete. For maintenance therapy following healing of erosive esophagitis, the recommended adult oral dosage of pantoprazole is 40 mg daily. Although the American College of Gastroenterology (ACG) states that chronic, even lifelong, therapy with a proton-pump inhibitor is appropriate in many patients with GERD, the manufacturer states that the safety and efficacy of continuing pantoprazole maintenance therapy for more than 1 year has not been established.

For the treatment of GERD associated with a history of erosive esophagitis, the recommended adult IV dosage of pantoprazole is 40 mg once daily. Treatment with IV pantoprazole should be discontinued as soon as the patient is able to initiate or resume treatment with the oral drug; safety and efficacy of IV pantoprazole use for more than 10 days have not been established.

For the treatment of pathologic GI hypersecretory conditions (e.g., Zollinger-Ellison syndrome, multiple endocrine neoplasia type I), the recommended adult oral dosage of pantoprazole is 40 mg twice daily. Dosages should be individualized and continued for as long as clinically necessary. Oral dosages up to 240 mg daily have been administered, and some patients have received the drug for more than 2 years.

The recommended adult IV dosage of pantoprazole for the treatment of pathologic GI hypersecretory conditions is 80 mg administered IV every 12 hours. In patients requiring a higher daily dosage, 80 mg administered IV every 8 hours is expected to maintain acid output below 10 mEq/hour. Safety and efficacy of dosages exceeding 240 mg daily, and use of IV pantoprazole for longer than 6 days have not been established.

Special Populations Sorry No Image

Dosage adjustment is not necessary in patients with renal impairment, patients undergoing hemodialysis, patients with hepatic impairment, or in geriatric patients. However, dosages exceeding 40 mg daily have not been studied in patients with hepatic impairment.


۲ - A to Z Drug Facts (A2zDrugs™) | Version: 15.0.1/2012.1.18



Route/Dosage

Maintenance of Healing of Erosive Esophagitis

Adults: PO 40 mg/day.

Pathological Hypersecretion Conditions Including Zollinger-Ellison Syndrome

Adults: PO Recommended starting dosage is 40 mg twice daily, adjusting the dose to the patient's needs and continuing therapy as long as clinically indicated. Dosages up to 240 mg/day have been used. IV 80 mg every 12 h; based upon individual patient needs, the dosage may be increased to 80 mg every 8 h. Daily dosages of more than 240 mg or administered for more than 6 days have not been studied.

Treatment of Erosive Esophagitis Associated With GERD

Adults: PO 40 mg/day for up to 8 wk; an additional 8-wk course of treatment may be considered in patients who have not healed after 8 wk. IV 40 mg/day for 7 to 10 days.

Delayed-release oral suspension

To administer in apple juice, empty contents of 1 packet of granules into a small cup containing 5 mL of apple juice. Stir for 5 sec and swallow immediately. To ensure complete delivery of the dose, rinse the container once or twice with apple juice to remove any remaining granules and have patient swallow immediately.
For patients who have a nasogastric (NG) tube, separate the plunger from the barrel of a 2 oz (60 mL) catheter tip syringe. Connect the catheter tip of the syringe to a 16 French (or larger) NG tube. Hold the syringe attached to the tubing as high as possible during application to prevent any bending of the tubing and to provide smooth flow of the contents under gravity. Empty the contents of the packet into the barrel of the syringe. Add 10 mL of apple juice and gently tap and/or shake the barrel of the syringe to help rinse the syringe and NG tube. Repeat with at least 2 additional 10 mL aliquots of apple juice. No granules should remain in the syringe. Make sure NG tube is not clogged to ensure the patient receives the full dose.
To administer in applesauce, open 1 packet and sprinkle intact granules on 1 teaspoonful of applesauce. Swallow within 10 min of preparation.

Administer approximately 30 min prior to a meal.

Administer only in apple juice or applesauce, not in water or other liquids or food.

Delayed-release tablets

May be used concomitantly with antacids.
Administer without regard to meals but administer with food if GI upset occurs.

Instruct patient to swallow tablet whole and not to split, chew, or crush the tablet.

Injection

For IV administration only. Not for intradermal, subcutaneous, IM, or intra-arterial administration.
Discontinue IV as soon as oral therapy is feasible.
Infuse prescribed dose through a dedicated line or Y-site over a period of 2 or 15 min as ordered. Flush IV line before and after administration of pantoprazole with dextrose 5% injection, sodium chloride 0.9% injection, or Ringer's lactate injection.
For 2-min infusion of 40 mg dose, reconstitute 1 vial of powder for injection with 10 mL of sodium chloride 0.9% injection to produce a solution with a final concentration of 4 mg/mL. Infuse total volume over a period of 2 min.
For 2-min infusion of 80 mg dose, reconstitute each of 2 vials of powder for injection with 10 mL of sodium chloride 0.9% injection to produce a solution with a final concentration of 4 mg/mL. Infuse total volume from both vials IV over a period of 2 min.
For 15-min infusion of 40 mg dose, reconstitute 1 vial with 10 mL of sodium chloride 0.9% injection. Further dilute (admix) with 100 mL of dextrose 5% injection, sodium chloride 0.9% injection, or Ringer's lactate injection to a total volume of 110 mL, producing a solution with a final concentration of approximately 0.4 mg/mL. Administer at a rate of 7 mL/min over 15 min.

For 15-min infusion of 80 mg dose, reconstitute each of 2 vials with 10 mL of sodium chloride 0.9% injection. Combine contents of 2 vials and further dilute (admix) with 80 mL of dextrose 5% injection, sodium chloride 0.9% injection, or Ringer's lactate injection to a total volume of 100 mL, producing a solution with a final concentration of approximately 0.8 mg/mL. Administer at a rate of 7 mL/min over 15 min.

Do not administer if particulate matter, cloudiness, or discoloration is noted.
Discard any unused reconstituted or admixed solution. Do not save for future use.

Store tablets and granules for oral suspension at 68° to 77°F. Store injection at 59° to 86°F. Protect powder for injection from light. Reconstituted solution may be stored for up to 6 h at room temperature prior to further dilution. Admixed solution may be stored for up to 24 h at room temperature prior to IV infusion.


۳- Nursing 2012 Drug Handbook (NDH12™) | Version: 14.0.4/2011.11.28

Indications & Dosages

Erosive esophagitis with gastroesophageal reflux disease (GERD)

Adults: 40 mg P.O. once daily for up to 8 weeks. For patients who haven't healed after 8 weeks of treatment, another 8-week course may be considered.

Short-term treatment of GERD in patients who can't take delayed-release tablets orally

Adults: 40 mg I.V. daily for 7 to 10 days.

Short-term treatment of GERD linked to history of erosive esophagitis

Adults: 40 mg I.V. once daily for 7 to 10 days. Switch to P.O. form as soon as patient is able to take orally.

Long-term maintenance of healing erosive esophagitis and reduction in relapse rates of daytime and nighttime heartburn symptoms in patients with GERD

Adults: 40 mg P.O. once daily.

Short-term treatment of pathologic hypersecretion caused by Zollinger-Ellison syndrome or other neoplastic conditions

Adults: Individualize dosage. Usual dose is 80 mg I.V. every 12 hours for no more than 6 days. For those needing a higher dose, 80 mg every 8 hours is expected to maintain acid output below 10 mEq/hour. Maximum daily dose is 240 mg/day.

Long-term treatment of pathologic hypersecretory conditions, including Zollinger-Ellison syndrome

Adults: Individualize dosage. Usual starting dose is 40 mg P.O. b.i.d. Adjust dose to a maximum of 240 mg/day. Stop I.V. drug when P.O. drug is warranted.


۴- British National Formulary 59th edition (BNF™) | Version: 13.0.5/2010.7.6

Dose

By mouth, benign gastric ulcer, ADULT over 18 years, 40 mg daily in the morning for 4 weeks, continued for further 4 weeks if not fully healed
Gastro-oesophageal reflux disease, ADULT and CHILD over 12 years, 20–40 mg daily in the morning for 4 weeks, continued for further 4 weeks if not fully healed; maintenance 20 mg daily, increased to 40 mg daily if symptoms return
Duodenal ulcer, ADULT over 18 years, 40 mg daily in the morning for 2 weeks, continued for further 2 weeks if not fully healed
Duodenal ulcer associated with Helicobacter pylori, see Recommended Regimens for Helicobacter pylori Eradication
Prophylaxis of NSAID-associated gastric or duodenal ulcer in patients with an increased risk of gastroduodenal complications who require continued NSAID treatment, ADULT over 18 years, 20 mg daily
Zollinger–Ellison syndrome (and other hypersecretory conditions), ADULT over 18 years, initially 80 mg once daily adjusted according to response (ELDERLY max. 40 mg daily); daily doses above 80 mg given in 2 divided doses

By intravenous injection over at least 2 minutes or by intravenous infusion, ADULT over 18 years, duodenal ulcer, gastric ulcer, and gastro-oesophageal reflux, 40 mg daily until oral administration can be resumed
Zollinger–Ellison syndrome (and other hypersecretory conditions), ADULT over 18 years, initially 80 mg (160 mg if rapid acid control required) then 80 mg once daily adjusted according to response; daily doses above 80 mg given in 2 divided doses


۵- Mosby's Nursing Drug Reference (RnDrug12™) | Version: 14.0.2/2011.9.28

Dosage and Routes

GERD navigator

Adult: PO 40 mg/day × 8 wk, may repeat course

Erosive esophagitis navigator

Adult: IV 40 mg/day × 7-10 day; PO 40 mg/day × 8 wk; may repeat PO course

Pathologic hypersecretory conditions navigator

Adult: PO 40 mg bid; IV 80 mg q12hr, max 240 mg/day

Duodenal ulcer/gastric ulcer/NSAID ulcer prophylaxis (unlabeled) navigator

Adult: PO 40 mg/day

H. pylori–associated ulcers (unlabeled) navigator

Adult: PO 40 mg bid; may be used with other products

Available forms: Delayed rel tabs 20, 40 mg; powder for inj 40 mg/vial; del rel granules for susp 40 mg


۶-Jones and Bartlett's 2012 Nurse's Drug Handbook | Version: 14.0.3/2012.1.30

 

Indications and Dosages

To treat gastroesophageal reflux disease (GERD)

DELAYED-RELEASE TABLETS navigator

Adults. 40 mg daily for up to 8 wk. Repeated for another 4 to 8 wk if healing doesn't occur.

I.V. INFUSION navigator

Adults. 40 mg daily infused over 2 min or 15 min for 7 to 10 days, followed by oral doses.

To maintain healing of erosive esophagitis and reduce relapse of daytime and nighttime symptoms in patients with GERD

DELAYED-RELEASE TABLETS navigator

Adults. 40 mg daily for up to 12 mo.

To treat pathological hypersecretion associated with Zollinger-Ellison syndrome or other neoplastic conditions

I.V. INFUSION navigator

Adults. 80 mg every 12 hr infused over 2 min or 15 min; adjusted based on patient's acid output measurements up to 80 mg every 8 hr.

Route Onset Peak Duration
P.O. 1 day 1 wk 1 wk
I.V. 1 day Unknown 1 wk

 


۷- DRUG GUIDE for Physicians (DrDrugs®) | Version: 14.3.1/2011.10.26

GERD navigator.gif

PO (Adults): 40 mg once daily.
PO (Children ge.gif5 yr): 15–39 kg–20 mg once daily for up to 8 wk; ge.gif40 kg–40 mg once daily for up to 8 wk.

IV (Adults): 40 mg once daily for 7–10 days.

Gastric Hypersecretory Conditions navigator.gif

PO (Adults): 40 mg twice daily, up to 120 mg twice daily.

IV (Adults): 80 mg q 12 hr (up to 240 mg/day).


۸- Pearson Nurse's Drug Guide | Version: 14.0.2/2011.7.25

Route & Dosage

Erosive Esophagitis navigator

Adult: PO 40 mg daily × 8–16 wks IV 40 mg daily × 7–10 days

Hypersecretory Disease navigator

Adult: PO 40 mg b.i.d. (doses up to 240 mg/day have been used) IV 80 mg b.i.d.; adjust based on acid output

Renal Impairment/Hepatic Impairment Dosage Adjustment navigator

Adjustment not needed

Hemodialysis Dosage Adjustment navigator

Drug not removed


۹ - Saunders Nursing Drug Handbook 2010 (Saunders-Dx™) | Version: 12.0.3/2009.11.25

Administration

ADMINISTRATION/HANDLINGnavigator

IV

Reconstitution

Mix 40-mg vial with 10 ml 0.9% NaCl injection.
May be further diluted with 100 ml D5W, 0.9% NaCl, or lactated Ringer's.

Rate of administration

Infuse 10 ml solution over at least 2 min.

Infuse 100 ml solution over at least 15 min.

Storage

Refrigerate vials. Store provided in-line filter at room temperature.

Once diluted with 10 ml 0.9% NaCl, stable for 2 hrs at room temperature; when further diluted with 100 ml, stable for 22 hrs at room temperature.

PO

Give without regard to meals.

Do not crush, chew, split tablets; swallow whole.

IV INCOMPATIBILITIES navigator

Do not mix with other medications. Flush IV with D5W, 0.9% NaCl, or lactated Ringer's solution before and after administration.


۱۰- 2010 Lippincott's Nursing Drug Guide (LNDG10™) | Version: 12.0.3/2009.12.18

Adults navigator

40 mg PO daily for maintenance healing of erosive esophagitis for 8 wk or less. The 8-wk course may be repeated if healing has not occurred; give continually for hypersecretory disorders; 40 mg/day IV for 7–10 days. Up to 240 mg/day PO or IV has been used for severe hypersecretory syndromes.

Pediatric patients younger than 18 yr navigator

Safety and efficacy not established.

Patients with hepatic impairment navigator

Use caution and monitor patient closely.


۱۱ - Clinician's Pocket Drug Reference 2009 (ClinRx™) | Version: 12.0.4/2009.9.15

Dose

40 mg/d PO; do not crush/chew tabs; 40 mg IV/d (not >3 mg/min, use Protonix filter)


 

مرتبط :

مقایسه کتابهای اطلاعات دارویی : تجویز دوز

مقایسه کتابهای اطلاعات دارویی : عوارض دارویی

 

 


برچسب‌ها: مقایسه نرم افزارها, تجویز و دوز
نوشته شده توسط هادی(نوید) اخوت پور در 19:0 جمعه چهاردهم بهمن 1390 |  لینک مطلب   نظرات :